Regarding Bromley's comment on Canadian research and HarryZ's followup, here is a little passage from BioMS's quarterly results released on November 14...
Pivotal Multiple Sclerosis Trial Update
BioMS Medical is currently enrolling patients across Canada, the U.K. and Sweden in its pivotal phase II/III clinical trial evaluating MBP8298 for the treatment of secondary progressive multiple sclerosis (SPMS). BioMS anticipates completing enrolment in the first part of 2006. To date the trial has successfully completed two safety reviews by its independent Data Safety Monitoring Board.
"We are pleased with the progress being made with this trial," said Mr. Kevin Giese, President of BioMS Medical. "Subsequent to the time-intensive enrolment of the first 100 patients who required extensive safety analysis and were being recruited from a limited number of sites, enrolment is accelerating nicely as the balance of the participating sites are coming on stream and contributing patients to the study. We will continue to provide updates on enrolment as milestones are reached."
http://biz.yahoo.com/cnw/051114/bioms_q ... .html?.v=1